Alimentary Pharmacology & Therapeutics

Papers
(The H4-Index of Alimentary Pharmacology & Therapeutics is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?135
Impact of thiopurine discontinuation at anti‐tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study135
Editorial: natural history of hepatitis delta virus‐induced liver disease ‐ less severe today but still needs attention133
Editorial: withdrawal of anti TNF‐alpha ‐ are we ready for biological therapy cycling?106
Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non‐cirrhotic patients with chronic hepatitis B98
75
Letter: confounders and outcomes in studies of beta‐blockers in liver disease—role of PPIs?70
Editorial: recognising the efficacy of licensed drug therapies for IBS on bloating—a step in the right direction for targeted treatment?69
Editorial: tissue findings fail to predict disease activity or prognosis in microscopic colitis: an opportunity to look at the molecular level66
Editorial: is there a ‘precursor’ HCC lesion and can it be detected by hepatobiliary contrast‐enhanced magnetic resonance imaging? Authors' reply65
Issue Information63
Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients63
Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs—authors' reply62
Editorial: the acid test—can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply61
Randomised clinical trial: effects of MD‐7246 on irritable bowel syndrome with diarrhoea61
Issue Information60
Editorial: the acid test – can bile acids predict recurrence of Clostridioides difficile infection?58
Editorial: ustekinumab during pregnancy—reassuring but still not enough. Authors' reply57
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor‐induced colitis55
Editorial: ‘Talis pater, talis filius’55
54
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough52
Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment51
Review article: vascular effects of PPARs in the context of NASH50
Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID‐19 pandemic: the PREPARE‐IBD multicentre cohort study49
Editorial: Exploring the influence of diet on later‐onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia? Authors' reply49
Editorial: the burden of alcohol‐related liver disease emergency admissions in England may be twice as high as previously thought49
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis48
Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom46
Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment46
45
Letter: loss of response to anti‐TNFα agents in patients with inflammatory bowel disease depends on treatment duration44
Issue Information44
Review article: current and future treatment approaches for IBS with constipation43
Issue Information43
Issue Information43
Letter: towards gender‐stratified colorectal cancer screening and surveillance? Authors’ reply42
41
Editorial: cannabis use disorders at the emergency department, a sign of a growing cannabinoid emergency41
Issue Information41
Editorial: what is needed to achieve success in developing diagnostic technologies for patients with gastrointestinal motility disorders ‐ past and present. Authors' reply40
Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack?40
0.15525603294373